You are viewing: India Minimal Residual Disease Market analysis

The India Minimal Residual Disease Market was valued at $22.1 Million in 2024 and projected to reach to $41.7 Million by 2029, representing a compound annual growth rate of 13.5%. India's Minimal Residual Disease market is poised for sustained growth driven by increasing cancer prevalence, healthcare infrastructure development, and rising awareness among oncologists and hematologists.

India Minimal Residual Disease Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Minimal Residual Disease Market Trends and Insights

  • This growth trajectory reflects India's increasing adoption of advanced diagnostic technologies and rising prevalence of hematologic malignancies.
  • India's healthcare infrastructure is progressively integrating MRD testing into clinical protocols, driven by growing awareness among oncologists and improved access to molecular diagnostics across major metropolitan centers and emerging tier-2 cities. The 13.5% compound annual growth rate in India significantly outpaces global benchmarks, underscoring the country's accelerating demand for precision oncology solutions.
  • India's expanding patient population, coupled with government initiatives supporting cancer diagnostics and treatment, creates a favorable environment for MRD market penetration.
  • By 2029, India is expected to consolidate its position as a key growth market within the Asia Pacific region, with increasing investments in laboratory infrastructure and rising healthcare expenditure supporting sustained market expansion..

Key Market Statistics

  • CAGR (2024-2029) 13.5% CAGR
  • Market Size, 2024 ~USD 22.1 Million
  • Forecast, 2029 ~USD 41.7 Million
  • Country India

India Minimal Residual Disease Market Overview

Market Valuation Growth :

India's MRD market is valued at $22.1 million in 2024 and is projected to reach $41.7 million by 2029, representing an impressive 13.5% CAGR, outpacing the global growth rate of 12.2%.

Rising Hematologic Malignancy Prevalence :

Increasing incidence of blood cancers and leukemias in India is driving demand for advanced MRD diagnostic solutions to improve patient outcomes and enable early intervention strategies.

Healthcare Infrastructure Modernization :

Indian healthcare facilities are progressively integrating MRD testing into clinical protocols, supported by government initiatives and private sector investments in diagnostic capabilities.

Technology Adoption Acceleration :

Growing adoption of flow cytometry, PCR-based testing, and next-generation sequencing technologies in Indian diagnostic centers is expanding MRD testing accessibility across tier-1 and tier-2 cities.

India Minimal Residual Disease Market Dynamics

  • The integration of MRD testing into standard treatment protocols for leukemia and lymphoma patients is becoming more prevalent across major metropolitan centers and emerging healthcare hubs.
  • Government healthcare initiatives and private diagnostic laboratory expansion are facilitating broader access to MRD testing technologies.
  • The market is expected to benefit from declining diagnostic costs and improved reimbursement policies.
  • By 2029, India's MRD market will likely establish itself as a critical component of precision oncology, with significant opportunities for diagnostic companies and healthcare providers to capture growing demand from both urban and semi-urban regions..

Related Ecosystem

Analytical And Scientific Instrumentation

Top Technologies
  • Environmental Testing
  • Gas Chromatography
  • Polymerase Chain Reaction (PCR)
  • Automated Liquid Handling Systems
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Shimadzu Corporation
  • Merck KGaA

    Diagnostic Imaging

    Top Technologies
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • CT Scanners
    • Nuclear Imaging
    • Positron Emission Tomography
    Top Companies
    • Siemens healthineers
    • PHILIPS HEALTHCARE
    • CANON INC.
    • FUJIFILM Holdings Corporation
    • UNITED IMAGING HEALTHCARE CO., LTD.

      In Vitro Diagnostics

      Top Technologies
      • Polymerase Chain Reaction (PCR)
      • Enzyme-Linked Immunosorbent Assay (ELISA)
      • Dna Microarrays
      • Assay Kits
      • Microarrays
      Top Companies
      • ROCHE HOLDINGS AG
      • Thermo Fisher Scientific Inc.
      • Danaher Corporation
      • Abbott Laboratories
      • Biomerieux s.a.

        Key Takeaways

        • India's MRD market is valued at $22.1 million in 2024 and is forecast to grow to $41.7 million by 2029, representing an 88.7% increase over the five-year period.
        • India's 13.5% CAGR outpaces the global average of 12.2%, positioning India as one of the fastest-growing MRD markets in the Asia Pacific region.
        • Rising prevalence of hematologic malignancies and increasing adoption of precision oncology diagnostics are primary drivers of India's accelerated market growth.
        • India's expanding healthcare infrastructure and government support for cancer diagnostics are creating favorable conditions for MRD testing adoption across urban and emerging markets.

        Minimal Residual Disease Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment MULTIPLE MYELOMA (Application)
        Forecast Period 2024-2029
        Growth Rate CAGR of 12.2% from 2024 to 2029
        Largest Segment ASSAY KITS & REAGENTS (Product)
        Market Size Base Year (Billions) ~USD 1.43 (2024)
        Revenue Forecast (Billions) ~USD 2.55 (2029)
        Segments Covered Product, Technology, Application, Type, End User

        India Minimal Residual Disease Market Report Segmentation

        5 segment dimensions are covered across the global market.

        By Product

        • Assay Kits & Reagents
        • Instruments

        By Technology

        • Flow Cytometry
        • Next-Generation Sequencing
        • Other Technologies
        • Polymerase Chain Reaction

        By Application

        • Hematological Malignancies
        • Multiple Myeloma
        • Other Applications
        • Solid Tumors

        By Type

        • Hodgkin Lymphoma
        • Leukemia
        • Lymphoblastic Leukemia
        • Lymphocytic Leukemia
        • Lymphoma
        • Myeloid Leukemia
        • Non-Hodgkin Lymphoma
        • Other Leukemias

        By End User

        • Academic & Research Institutes
        • Diagnostic Laboratories
        • Hospitals & Specialty Clinics
        • Other End Users

        INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029

        Segment20222023202420252026202720282029CAGR (%)
        ACADEMIC & RESEARCH INSTITUTES3.84.355.66.47.38.29.313.2
        DIAGNOSTIC LABORATORIES89.210.712.414.316.418.821.615.1
        HOSPITALS & SPECIALTY CLINICS11.613.415.117.319.622.225.228.213.3
        OTHER END USERS22.32.73.13.544.55.113.6
        TOTAL25.429.233.538.443.849.956.764.213.9

        Target Audience

        • Diagnostic Equipment Manufacturers : Need India-specific market data to develop localized product strategies, understand adoption barriers, and identify opportunities for flow cytometry and sequencing technology deployment across Indian healthcare facilities.
        • Healthcare Investment Firms : Require detailed market sizing and growth projections for India to evaluate investment opportunities in diagnostic companies, hospital networks, and healthcare technology startups operating in the MRD space.
        • Pharmaceutical & Oncology Companies : Need India market insights to align clinical trial strategies, companion diagnostic development, and treatment protocol adoption with local MRD testing capabilities and healthcare infrastructure.
        • Diagnostic Laboratory Operators : Seek India-focused market analysis to assess expansion opportunities, competitive positioning, technology investment requirements, and revenue potential for MRD testing service offerings.
        • Healthcare Policy & Government Bodies : Require market intelligence on MRD testing adoption, infrastructure gaps, and growth trends to inform healthcare policy decisions, diagnostic center development, and cancer care program planning in India.

        Reasons to Buy this Report

        • Market Size & Growth Validation : Obtain precise market valuation data for India's MRD segment with verified CAGR of 13.5%, enabling accurate financial forecasting and investment decision-making for the 2024-2029 period.
        • Regional Competitive Intelligence : Understand India-specific market dynamics, competitive landscape, and key players driving MRD adoption to identify partnership opportunities and market entry strategies tailored to Indian healthcare systems.
        • Healthcare Infrastructure Insights : Access detailed analysis of India's diagnostic infrastructure modernization, hospital adoption rates, and technology integration patterns to align product development and distribution strategies.
        • Regulatory & Reimbursement Landscape : Gain comprehensive understanding of India-specific regulatory requirements, government healthcare policies, and reimbursement frameworks affecting MRD testing adoption and market accessibility.
        • Growth Opportunity Identification : Identify high-potential segments within India's MRD market, including emerging diagnostic centers, tier-2 city expansion opportunities, and underserved patient populations for targeted business development.

        Frequently asked questions

        What is the current market size of MRD testing in India?

        India's Minimal Residual Disease market was valued at $22.1 million in 2024 and is expected to reach $41.7 million by 2029.

        What is the projected growth rate for India's MRD market?

        India's MRD market is projected to grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2029.

        Why is India's MRD market growing faster than the global average?

        India's 13.5% CAGR exceeds the global 12.2% rate due to rising cancer prevalence, increasing adoption of precision diagnostics, expanding healthcare infrastructure, and government support for advanced oncology testing.

        Which factors are driving MRD market expansion in India?

        Key drivers include growing hematologic malignancy prevalence, increased awareness among oncologists, improved access to molecular diagnostics, rising healthcare expenditure, and government initiatives supporting cancer care infrastructure.

        How will India's MRD market evolve by 2029?

        By 2029, India is expected to consolidate its position as a leading MRD market in Asia Pacific, with widespread adoption across metropolitan and tier-2 cities, supported by continued infrastructure investments and healthcare spending growth.

        RESEARCH METHODOLOGY

        This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

        Secondary Research

        In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

        Primary Research

        In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

        The following is a breakdown of the primary respondents:

        Minimal Residual Disease Market

        Note 1: Others include sales managers, marketing managers, and product managers.

        Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

        To know about the assumptions considered for the study, download the pdf brochure

        COMPANY NAME DESIGNATION
        Roche Ltd. General Manager
        Gaurdant Area Sales Manager

        Market Size Estimation

        Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

        • The key players in the industry have been identified through extensive secondary research
        • The revenues generated by leading players operating in the minimal residual disease testing market have been determined through primary and secondary research
        • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

        The research methodology used to estimate the market size includes the following:

        Minimal Residual Disease Market

        Data Triangulation

        After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

        Market Definition

        Minimal Residual Disease (MRD) refers to the small number of cancer cells left in a body after cancer treatment. MRD tests are performed to diagnose and monitor patients with various hematology cancers, such as leukemia, lymphoma, and myeloma. An MRD test looks for cancer cells not killed by chemotherapy or other cancer treatments. Moreover, these tests also play a crucial role in clinical trials of hemato-oncology therapeutics.

        Stakeholders

        • Senior Management
        • End User
        • Finance/Procurement Department 
        • R&D Department

        Report Objectives

        • To define, describe, segment, and forecast the global minimal residual disease testing market by product, technology, application, end user, and region
        • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
        • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
        • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
        • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
        • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market
        • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

         

        Get the Full Minimal Residual Disease Market Report

        Full forecast, segment splits, and company analysis for all Minimal Residual Disease Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status